id	sid	tid	token	lemma	pos
egc-209	1	1	eglobal	eglobal	PROPN
egc-209	1	2	congress	congress	PROPN
egc-209	1	3	hosted	host	VERB
egc-209	1	4	online	online	ADV
egc-209	1	5	from	from	ADP
egc-209	1	6	dubai	dubai	PROPN
egc-209	1	7	,	,	PUNCT
egc-209	1	8	u.	u.	PROPN
egc-209	1	9	a.	a.	PROPN
egc-209	1	10	e.	e.	PROPN
egc-209	1	11	,	,	PUNCT
egc-209	1	12	e	e	PROPN
egc-209	1	13	conference	conference	NOUN
egc-209	1	14	.	.	PUNCT
egc-209	2	1	date	date	NOUN
egc-209	2	2	:	:	PUNCT
egc-209	2	3	29th	29th	ADJ
egc-209	2	4	may	may	AUX
egc-209	2	5	2024	2024	NUM
egc-209	2	6	website	website	NOUN
egc-209	2	7	:	:	PUNCT
egc-209	2	8	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN
egc-209	2	9	issn	issn	PROPN
egc-209	2	10	(	(	PUNCT
egc-209	2	11	e	e	NOUN
egc-209	2	12	):	):	PUNCT
egc-209	2	13	2836	2836	NUM
egc-209	2	14	-	-	SYM
egc-209	2	15	3612	3612	NUM
egc-209	2	16	19	19	NUM
egc-209	2	17	|	|	ADV
egc-209	2	18	p	p	NOUN
egc-209	2	19	a	a	DET
egc-209	2	20	g	g	NOUN
egc-209	2	21	e	e	NOUN
egc-209	2	22	expression	expression	NOUN
egc-209	2	23	of	of	ADP
egc-209	2	24	marker	marker	NOUN
egc-209	2	25	ki-67	ki-67	PUNCT
egc-209	2	26	in	in	ADP
egc-209	2	27	nephroblastomas	nephroblastoma	NOUN
egc-209	2	28	in	in	ADP
egc-209	2	29	children	child	NOUN
egc-209	2	30	matrasulov	matrasulov	PROPN
egc-209	2	31	r.	r.	PROPN
egc-209	2	32	s.	s.	PROPN
egc-209	2	33	tashkent	tashkent	PROPN
egc-209	3	1	medical	medical	PROPN
egc-209	3	2	academy	academy	PROPN
egc-209	3	3	relevance	relevance	NOUN
egc-209	3	4	over	over	ADP
egc-209	3	5	the	the	DET
egc-209	3	6	past	past	ADJ
egc-209	3	7	decades	decade	NOUN
egc-209	3	8	,	,	PUNCT
egc-209	3	9	oncology	oncology	NOUN
egc-209	3	10	services	service	NOUN
egc-209	3	11	have	have	AUX
egc-209	3	12	made	make	VERB
egc-209	3	13	great	great	ADJ
egc-209	3	14	strides	stride	NOUN
egc-209	3	15	,	,	PUNCT
egc-209	3	16	we	we	PRON
egc-209	3	17	have	have	AUX
egc-209	3	18	witnessed	witness	VERB
egc-209	3	19	unprecedented	unprecedented	ADJ
egc-209	3	20	changes	change	NOUN
egc-209	3	21	and	and	CCONJ
egc-209	3	22	significant	significant	ADJ
egc-209	3	23	advances	advance	NOUN
egc-209	3	24	in	in	ADP
egc-209	3	25	the	the	DET
egc-209	3	26	treatment	treatment	NOUN
egc-209	3	27	of	of	ADP
egc-209	3	28	malignant	malignant	ADJ
egc-209	3	29	tumors	tumor	NOUN
egc-209	3	30	both	both	CCONJ
egc-209	3	31	among	among	ADP
egc-209	3	32	adults	adult	NOUN
egc-209	3	33	and	and	CCONJ
egc-209	3	34	among	among	ADP
egc-209	3	35	children	child	NOUN
egc-209	3	36	and	and	CCONJ
egc-209	3	37	adolescents	adolescent	NOUN
egc-209	3	38	.	.	PUNCT
egc-209	4	1	the	the	DET
egc-209	4	2	objectives	objective	NOUN
egc-209	4	3	of	of	ADP
egc-209	4	4	the	the	DET
egc-209	4	5	study	study	NOUN
egc-209	4	6	are	be	AUX
egc-209	4	7	to	to	PART
egc-209	4	8	study	study	VERB
egc-209	4	9	and	and	CCONJ
egc-209	4	10	analyze	analyze	VERB
egc-209	4	11	the	the	DET
egc-209	4	12	level	level	NOUN
egc-209	4	13	of	of	ADP
egc-209	4	14	proliferative	proliferative	ADJ
egc-209	4	15	activity	activity	NOUN
egc-209	4	16	of	of	ADP
egc-209	4	17	ki-67	ki-67	ADJ
egc-209	4	18	in	in	ADP
egc-209	4	19	primary	primary	ADJ
egc-209	4	20	tumor	tumor	NOUN
egc-209	4	21	tissue	tissue	NOUN
egc-209	4	22	in	in	ADP
egc-209	4	23	childhood	childhood	NOUN
egc-209	4	24	and	and	CCONJ
egc-209	4	25	adolescent	adolescent	ADJ
egc-209	4	26	patients	patient	NOUN
egc-209	4	27	with	with	ADP
egc-209	4	28	embryonal	embryonal	ADJ
egc-209	4	29	tumors	tumor	NOUN
egc-209	4	30	(	(	PUNCT
egc-209	4	31	such	such	ADJ
egc-209	4	32	as	as	ADP
egc-209	4	33	nephroblastoma	nephroblastoma	ADJ
egc-209	4	34	)	)	PUNCT
egc-209	4	35	,	,	PUNCT
egc-209	4	36	as	as	ADV
egc-209	4	37	well	well	ADV
egc-209	4	38	as	as	ADP
egc-209	4	39	in	in	ADP
egc-209	4	40	tumor	tumor	NOUN
egc-209	4	41	tissue	tissue	NOUN
egc-209	4	42	after	after	ADP
egc-209	4	43	chemotherapy	chemotherapy	NOUN
egc-209	4	44	treatment	treatment	NOUN
egc-209	4	45	,	,	PUNCT
egc-209	4	46	to	to	PART
egc-209	4	47	evaluate	evaluate	VERB
egc-209	4	48	it	it	PRON
egc-209	4	49	as	as	ADP
egc-209	4	50	a	a	DET
egc-209	4	51	prognostic	prognostic	ADJ
egc-209	4	52	factor	factor	NOUN
egc-209	4	53	.	.	PUNCT
egc-209	5	1	materials	material	NOUN
egc-209	5	2	and	and	CCONJ
egc-209	5	3	methods	method	NOUN
egc-209	5	4	of	of	ADP
egc-209	5	5	research	research	NOUN
egc-209	5	6	this	this	DET
egc-209	5	7	study	study	NOUN
egc-209	5	8	was	be	AUX
egc-209	5	9	conducted	conduct	VERB
egc-209	5	10	on	on	ADP
egc-209	5	11	tumor	tumor	NOUN
egc-209	5	12	tissue	tissue	NOUN
egc-209	5	13	samples	sample	NOUN
egc-209	5	14	before	before	ADP
egc-209	5	15	the	the	DET
egc-209	5	16	start	start	NOUN
egc-209	5	17	of	of	ADP
egc-209	5	18	special	special	ADJ
egc-209	5	19	antitumor	antitumor	PROPN
egc-209	5	20	treatment	treatment	NOUN
egc-209	5	21	and	and	CCONJ
egc-209	5	22	after	after	ADP
egc-209	5	23	the	the	DET
egc-209	5	24	first	first	ADJ
egc-209	5	25	stage	stage	NOUN
egc-209	5	26	neoadjuvant	neoadjuvant	ADJ
egc-209	5	27	polychemotherapy	polychemotherapy	NOUN
egc-209	5	28	treatment	treatment	NOUN
egc-209	5	29	.	.	PUNCT
egc-209	6	1	all	all	DET
egc-209	6	2	patients	patient	NOUN
egc-209	6	3	included	include	VERB
egc-209	6	4	in	in	ADP
egc-209	6	5	the	the	DET
egc-209	6	6	study	study	NOUN
egc-209	6	7	were	be	AUX
egc-209	6	8	treated	treat	VERB
egc-209	6	9	at	at	ADP
egc-209	6	10	the	the	DET
egc-209	6	11	russian	russian	ADJ
egc-209	6	12	national	national	PROPN
egc-209	6	13	research	research	PROPN
egc-209	6	14	medical	medical	ADJ
egc-209	6	15	center	center	NOUN
egc-209	6	16	for	for	ADP
egc-209	6	17	oir	oir	PROPN
egc-209	6	18	in	in	ADP
egc-209	6	19	the	the	DET
egc-209	6	20	department	department	NOUN
egc-209	6	21	of	of	ADP
egc-209	6	22	pediatric	pediatric	ADJ
egc-209	6	23	oncology	oncology	NOUN
egc-209	6	24	from	from	ADP
egc-209	6	25	2012	2012	NUM
egc-209	6	26	to	to	ADP
egc-209	6	27	2022	2022	NUM
egc-209	6	28	.	.	PUNCT
egc-209	7	1	research	research	NOUN
egc-209	7	2	results	result	NOUN
egc-209	7	3	and	and	CCONJ
egc-209	7	4	discussion	discussion	NOUN
egc-209	7	5	when	when	SCONJ
egc-209	7	6	assessing	assess	VERB
egc-209	7	7	the	the	DET
egc-209	7	8	level	level	NOUN
egc-209	7	9	of	of	ADP
egc-209	7	10	proliferative	proliferative	ADJ
egc-209	7	11	activity	activity	NOUN
egc-209	7	12	of	of	ADP
egc-209	7	13	ki-67	ki-67	ADJ
egc-209	7	14	in	in	ADP
egc-209	7	15	nephroblastoma	nephroblastoma	ADJ
egc-209	7	16	tumor	tumor	NOUN
egc-209	7	17	tissue	tissue	NOUN
egc-209	7	18	(	(	PUNCT
egc-209	7	19	n=82	n=82	NOUN
egc-209	7	20	)	)	PUNCT
egc-209	7	21	before	before	ADP
egc-209	7	22	the	the	DET
egc-209	7	23	start	start	NOUN
egc-209	7	24	of	of	ADP
egc-209	7	25	special	special	ADJ
egc-209	7	26	treatment	treatment	NOUN
egc-209	7	27	and	and	CCONJ
egc-209	7	28	depending	depend	VERB
egc-209	7	29	on	on	ADP
egc-209	7	30	the	the	DET
egc-209	7	31	extent	extent	NOUN
egc-209	7	32	of	of	ADP
egc-209	7	33	the	the	DET
egc-209	7	34	tumor	tumor	NOUN
egc-209	7	35	process	process	NOUN
egc-209	7	36	,	,	PUNCT
egc-209	7	37	it	it	PRON
egc-209	7	38	was	be	AUX
egc-209	7	39	revealed	reveal	VERB
egc-209	7	40	that	that	SCONJ
egc-209	7	41	with	with	ADP
egc-209	7	42	the	the	DET
egc-209	7	43	extent	extent	NOUN
egc-209	7	44	of	of	ADP
egc-209	7	45	the	the	DET
egc-209	7	46	tumor	tumor	NOUN
egc-209	7	47	process	process	NOUN
egc-209	7	48	,	,	PUNCT
egc-209	7	49	the	the	DET
egc-209	7	50	level	level	NOUN
egc-209	7	51	of	of	ADP
egc-209	7	52	t	t	PROPN
egc-209	7	53	3	3	NUM
egc-209	7	54	ki-67	ki-67	VERB
egc-209	7	55	was	be	AUX
egc-209	7	56	higher	high	ADJ
egc-209	7	57	by	by	ADP
egc-209	7	58	34.2	34.2	NUM
egc-209	7	59	%	%	NOUN
egc-209	7	60	(	(	PUNCT
egc-209	7	61	53.0%±6.1	53.0%±6.1	NUM
egc-209	7	62	%	%	NOUN
egc-209	7	63	)	)	PUNCT
egc-209	7	64	,	,	PUNCT
egc-209	7	65	in	in	ADP
egc-209	7	66	contrast	contrast	NOUN
egc-209	7	67	to	to	ADP
egc-209	7	68	the	the	DET
egc-209	7	69	level	level	NOUN
egc-209	7	70	of	of	ADP
egc-209	7	71	ki-67	ki-67	ADJ
egc-209	7	72	at	at	ADP
egc-209	7	73	t	t	PROPN
egc-209	7	74	2	2	NUM
egc-209	7	75	(	(	PUNCT
egc-209	7	76	44.5%±4.2	44.5%±4.2	NUM
egc-209	7	77	%	%	NOUN
egc-209	7	78	)	)	PUNCT
egc-209	7	79	,	,	PUNCT
egc-209	7	80	an	an	DET
egc-209	7	81	increase	increase	NOUN
egc-209	7	82	in	in	ADP
egc-209	7	83	the	the	DET
egc-209	7	84	level	level	NOUN
egc-209	7	85	of	of	ADP
egc-209	7	86	ki-67	ki-67	ADJ
egc-209	7	87	in	in	ADP
egc-209	7	88	tumor	tumor	NOUN
egc-209	7	89	tissue	tissue	NOUN
egc-209	7	90	in	in	ADP
egc-209	7	91	patients	patient	NOUN
egc-209	7	92	with	with	ADP
egc-209	7	93	metastatic	metastatic	ADJ
egc-209	7	94	lesions	lesion	NOUN
egc-209	7	95	was	be	AUX
egc-209	7	96	also	also	ADV
egc-209	7	97	found	find	VERB
egc-209	7	98	lymph	lymph	NOUN
egc-209	7	99	nodes	node	NOUN
egc-209	7	100	(	(	PUNCT
egc-209	7	101	by	by	ADP
egc-209	7	102	39	39	NUM
egc-209	7	103	%	%	NOUN
egc-209	7	104	)	)	PUNCT
egc-209	7	105	and	and	CCONJ
egc-209	7	106	with	with	ADP
egc-209	7	107	distant	distant	ADJ
egc-209	7	108	metastasis	metastasis	NOUN
egc-209	7	109	(	(	PUNCT
egc-209	7	110	by	by	ADP
egc-209	7	111	21.2	21.2	NUM
egc-209	7	112	%	%	NOUN
egc-209	7	113	)	)	PUNCT
egc-209	7	114	.	.	PUNCT
egc-209	8	1	it	it	PRON
egc-209	8	2	was	be	AUX
egc-209	8	3	reliably	reliably	ADV
egc-209	8	4	established	establish	VERB
egc-209	8	5	that	that	SCONJ
egc-209	8	6	there	there	PRON
egc-209	8	7	was	be	VERB
egc-209	8	8	a	a	DET
egc-209	8	9	decrease	decrease	NOUN
egc-209	8	10	in	in	ADP
egc-209	8	11	the	the	DET
egc-209	8	12	level	level	NOUN
egc-209	8	13	of	of	ADP
egc-209	8	14	proliferative	proliferative	ADJ
egc-209	8	15	activity	activity	NOUN
egc-209	8	16	of	of	ADP
egc-209	8	17	ki-67	ki-67	ADJ
egc-209	8	18	in	in	ADP
egc-209	8	19	tumor	tumor	NOUN
egc-209	8	20	tissue	tissue	NOUN
egc-209	8	21	depending	depend	VERB
egc-209	8	22	on	on	ADP
egc-209	8	23	the	the	DET
egc-209	8	24	initial	initial	ADJ
egc-209	8	25	size	size	NOUN
egc-209	8	26	of	of	ADP
egc-209	8	27	the	the	DET
egc-209	8	28	tumor	tumor	NOUN
egc-209	8	29	node	node	NOUN
egc-209	8	30	after	after	ADP
egc-209	8	31	special	special	ADJ
egc-209	8	32	treatment	treatment	NOUN
egc-209	8	33	:	:	PUNCT
egc-209	8	34	at	at	ADP
egc-209	8	35	t	t	PROPN
egc-209	8	36	2	2	NUM
egc-209	8	37	it	it	PRON
egc-209	8	38	was	be	AUX
egc-209	8	39	16.02	16.02	NUM
egc-209	8	40	%	%	NOUN
egc-209	8	41	±	±	NUM
egc-209	8	42	2.3	2.3	NUM
egc-209	8	43	%	%	NOUN
egc-209	8	44	(	(	PUNCT
egc-209	8	45	p	p	X
egc-209	8	46	=	=	NOUN
egc-209	8	47	0.0221	0.0221	NUM
egc-209	8	48	)	)	PUNCT
egc-209	8	49	,	,	PUNCT
egc-209	8	50	and	and	CCONJ
egc-209	8	51	at	at	ADP
egc-209	8	52	t	t	PROPN
egc-209	8	53	3	3	NUM
egc-209	8	54	was	be	AUX
egc-209	8	55	42.5%±5.01	42.5%±5.01	NUM
egc-209	8	56	%	%	NOUN
egc-209	8	57	(	(	PUNCT
egc-209	8	58	p=0.0015	p=0.0015	PROPN
egc-209	8	59	)	)	PUNCT
egc-209	8	60	.	.	PUNCT
egc-209	9	1	the	the	DET
egc-209	9	2	presence	presence	NOUN
egc-209	9	3	of	of	ADP
egc-209	9	4	metastatic	metastatic	ADJ
egc-209	9	5	lesions	lesion	NOUN
egc-209	9	6	of	of	ADP
egc-209	9	7	nearby	nearby	ADJ
egc-209	9	8	lymph	lymph	NOUN
egc-209	9	9	nodes	node	NOUN
egc-209	9	10	had	have	VERB
egc-209	9	11	a	a	DET
egc-209	9	12	lesser	less	ADJ
egc-209	9	13	influence	influence	NOUN
egc-209	9	14	on	on	ADP
egc-209	9	15	the	the	DET
egc-209	9	16	ki-67	ki-67	ADJ
egc-209	9	17	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN
egc-209	9	18	eglobal	eglobal	PROPN
egc-209	9	19	congress	congress	PROPN
egc-209	9	20	hosted	host	VERB
egc-209	9	21	online	online	ADV
egc-209	9	22	from	from	ADP
egc-209	9	23	dubai	dubai	PROPN
egc-209	9	24	,	,	PUNCT
egc-209	9	25	u.	u.	PROPN
egc-209	9	26	a.	a.	PROPN
egc-209	9	27	e.	e.	PROPN
egc-209	9	28	,	,	PUNCT
egc-209	9	29	e	e	PROPN
egc-209	9	30	conference	conference	NOUN
egc-209	9	31	.	.	PUNCT
egc-209	10	1	date	date	NOUN
egc-209	10	2	:	:	PUNCT
egc-209	10	3	29th	29th	ADJ
egc-209	10	4	may	may	AUX
egc-209	10	5	2024	2024	NUM
egc-209	10	6	website	website	NOUN
egc-209	10	7	:	:	PUNCT
egc-209	10	8	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN
egc-209	10	9	issn	issn	PROPN
egc-209	10	10	(	(	PUNCT
egc-209	10	11	e	e	NOUN
egc-209	10	12	):	):	PUNCT
egc-209	10	13	2836	2836	NUM
egc-209	10	14	-	-	SYM
egc-209	10	15	3612	3612	NUM
egc-209	10	16	20	20	NUM
egc-209	10	17	|	|	ADV
egc-209	10	18	p	p	X
egc-209	10	19	a	a	DET
egc-209	10	20	g	g	NOUN
egc-209	10	21	e	e	NOUN
egc-209	10	22	expression	expression	NOUN
egc-209	10	23	level	level	NOUN
egc-209	10	24	after	after	ADP
egc-209	10	25	treatment	treatment	NOUN
egc-209	10	26	,	,	PUNCT
egc-209	10	27	which	which	PRON
egc-209	10	28	was	be	AUX
egc-209	10	29	35.3	35.3	NUM
egc-209	10	30	%	%	NOUN
egc-209	10	31	±	±	NUM
egc-209	10	32	4.1	4.1	NUM
egc-209	10	33	%	%	NOUN
egc-209	10	34	(	(	PUNCT
egc-209	10	35	p	p	NOUN
egc-209	10	36	=	=	NOUN
egc-209	10	37	0.0024	0.0024	NUM
egc-209	10	38	)	)	PUNCT
egc-209	10	39	for	for	ADP
egc-209	10	40	n	n	PROPN
egc-209	10	41	0	0	NUM
egc-209	10	42	,	,	PUNCT
egc-209	10	43	56.4	56.4	NUM
egc-209	10	44	%	%	NOUN
egc-209	10	45	±	±	NOUN
egc-209	10	46	for	for	ADP
egc-209	10	47	n	n	PROPN
egc-209	10	48	1	1	NUM
egc-209	10	49	6.42	6.42	NUM
egc-209	10	50	%	%	NOUN
egc-209	10	51	(	(	PUNCT
egc-209	10	52	p=0.0021	p=0.0021	NOUN
egc-209	10	53	)	)	PUNCT
egc-209	10	54	.	.	PUNCT
egc-209	11	1	the	the	DET
egc-209	11	2	change	change	NOUN
egc-209	11	3	in	in	ADP
egc-209	11	4	ki-67	ki-67	ADJ
egc-209	11	5	in	in	ADP
egc-209	11	6	the	the	DET
egc-209	11	7	residual	residual	ADJ
egc-209	11	8	tumor	tumor	NOUN
egc-209	11	9	tissue	tissue	NOUN
egc-209	11	10	in	in	ADP
egc-209	11	11	the	the	DET
egc-209	11	12	presence	presence	NOUN
egc-209	11	13	of	of	ADP
egc-209	11	14	distant	distant	ADJ
egc-209	11	15	metastatic	metastatic	ADJ
egc-209	11	16	lesions	lesion	NOUN
egc-209	11	17	had	have	VERB
egc-209	11	18	multidirectional	multidirectional	ADJ
egc-209	11	19	significance	significance	NOUN
egc-209	11	20	,	,	PUNCT
egc-209	11	21	where	where	SCONJ
egc-209	11	22	its	its	PRON
egc-209	11	23	level	level	NOUN
egc-209	11	24	was	be	AUX
egc-209	11	25	84.3	84.3	NUM
egc-209	11	26	%	%	NOUN
egc-209	11	27	±	±	NUM
egc-209	11	28	6.2	6.2	NUM
egc-209	11	29	%	%	NOUN
egc-209	11	30	(	(	PUNCT
egc-209	11	31	p	p	NOUN
egc-209	11	32	=	=	NOUN
egc-209	11	33	0.0013	0.0013	NUM
egc-209	11	34	)	)	PUNCT
egc-209	11	35	,	,	PUNCT
egc-209	11	36	which	which	PRON
egc-209	11	37	is	be	AUX
egc-209	11	38	25	25	NUM
egc-209	11	39	%	%	NOUN
egc-209	11	40	higher	high	ADJ
egc-209	11	41	than	than	ADP
egc-209	11	42	before	before	ADP
egc-209	11	43	the	the	DET
egc-209	11	44	start	start	NOUN
egc-209	11	45	of	of	ADP
egc-209	11	46	special	special	ADJ
egc-209	11	47	treatment	treatment	NOUN
egc-209	11	48	.	.	PUNCT
egc-209	12	1	treatment	treatment	NOUN
egc-209	12	2	,	,	PUNCT
egc-209	12	3	when	when	SCONJ
egc-209	12	4	,	,	PUNCT
egc-209	12	5	in	in	ADP
egc-209	12	6	the	the	DET
egc-209	12	7	absence	absence	NOUN
egc-209	12	8	of	of	ADP
egc-209	12	9	metastatic	metastatic	ADJ
egc-209	12	10	lesions	lesion	NOUN
egc-209	12	11	,	,	PUNCT
egc-209	12	12	a	a	DET
egc-209	12	13	decrease	decrease	NOUN
egc-209	12	14	in	in	ADP
egc-209	12	15	the	the	DET
egc-209	12	16	level	level	NOUN
egc-209	12	17	of	of	ADP
egc-209	12	18	ki-67	ki-67	ADJ
egc-209	12	19	by	by	ADP
egc-209	12	20	3	3	NUM
egc-209	12	21	5	5	NUM
egc-209	12	22	%	%	NOUN
egc-209	12	23	(	(	PUNCT
egc-209	12	24	20.22	20.22	NUM
egc-209	12	25	%	%	NOUN
egc-209	12	26	±	±	NUM
egc-209	12	27	1.6	1.6	NUM
egc-209	12	28	%	%	NOUN
egc-209	12	29	(	(	PUNCT
egc-209	12	30	p	p	NOUN
egc-209	12	31	=	=	NOUN
egc-209	12	32	0.0019	0.0019	NUM
egc-209	12	33	)	)	PUNCT
egc-209	12	34	)	)	PUNCT
egc-209	12	35	was	be	AUX
egc-209	12	36	noted	note	VERB
egc-209	12	37	.	.	PUNCT
egc-209	13	1	when	when	SCONJ
egc-209	13	2	assessing	assess	VERB
egc-209	13	3	the	the	DET
egc-209	13	4	level	level	NOUN
egc-209	13	5	of	of	ADP
egc-209	13	6	proliferative	proliferative	ADJ
egc-209	13	7	activity	activity	NOUN
egc-209	13	8	of	of	ADP
egc-209	13	9	ki-67	ki-67	ADJ
egc-209	13	10	in	in	ADP
egc-209	13	11	tumor	tumor	NOUN
egc-209	13	12	tissue	tissue	NOUN
egc-209	13	13	represented	represent	VERB
egc-209	13	14	by	by	ADP
egc-209	13	15	nephroblastoma	nephroblastoma	NOUN
egc-209	13	16	,	,	PUNCT
egc-209	13	17	before	before	ADP
egc-209	13	18	the	the	DET
egc-209	13	19	start	start	NOUN
egc-209	13	20	of	of	ADP
egc-209	13	21	special	special	ADJ
egc-209	13	22	treatment	treatment	NOUN
egc-209	13	23	and	and	CCONJ
egc-209	13	24	depending	depend	VERB
egc-209	13	25	on	on	ADP
egc-209	13	26	the	the	DET
egc-209	13	27	prevalence	prevalence	NOUN
egc-209	13	28	of	of	ADP
egc-209	13	29	the	the	DET
egc-209	13	30	tumor	tumor	NOUN
egc-209	13	31	process	process	NOUN
egc-209	13	32	,	,	PUNCT
egc-209	13	33	the	the	DET
egc-209	13	34	following	following	NOUN
egc-209	13	35	was	be	AUX
egc-209	13	36	revealed	reveal	VERB
egc-209	13	37	:	:	PUNCT
egc-209	13	38	with	with	ADP
egc-209	13	39	the	the	DET
egc-209	13	40	prevalence	prevalence	NOUN
egc-209	13	41	of	of	ADP
egc-209	13	42	the	the	DET
egc-209	13	43	tumor	tumor	NOUN
egc-209	13	44	process	process	NOUN
egc-209	13	45	t	t	PROPN
egc-209	13	46	3	3	NUM
egc-209	13	47	,	,	PUNCT
egc-209	13	48	the	the	DET
egc-209	13	49	level	level	NOUN
egc-209	13	50	was	be	AUX
egc-209	13	51	52.5	52.5	NUM
egc-209	13	52	%	%	NOUN
egc-209	13	53	±	±	NUM
egc-209	13	54	4.5	4.5	NUM
egc-209	13	55	%	%	NOUN
egc-209	13	56	,	,	PUNCT
egc-209	13	57	which	which	PRON
egc-209	13	58	is	be	AUX
egc-209	13	59	lower	low	ADJ
egc-209	13	60	than	than	ADP
egc-209	13	61	the	the	DET
egc-209	13	62	level	level	NOUN
egc-209	13	63	at	at	ADP
egc-209	13	64	t	t	PROPN
egc-209	13	65	2	2	NUM
egc-209	13	66	(	(	PUNCT
egc-209	13	67	81.2	81.2	NUM
egc-209	13	68	%	%	NOUN
egc-209	13	69	±	±	NUM
egc-209	13	70	7.7	7.7	NUM
egc-209	13	71	%	%	NOUN
egc-209	13	72	(	(	PUNCT
egc-209	13	73	p	p	NOUN
egc-209	13	74	=	=	NOUN
egc-209	13	75	0.0002	0.0002	NUM
egc-209	13	76	)	)	PUNCT
egc-209	13	77	)	)	PUNCT
egc-209	13	78	,	,	PUNCT
egc-209	13	79	by	by	ADP
egc-209	13	80	more	more	ADJ
egc-209	13	81	than	than	ADP
egc-209	13	82	40	40	NUM
egc-209	13	83	%	%	NOUN
egc-209	13	84	,	,	PUNCT
egc-209	13	85	however	however	ADV
egc-209	13	86	,	,	PUNCT
egc-209	13	87	compared	compare	VERB
egc-209	13	88	with	with	ADP
egc-209	13	89	the	the	DET
egc-209	13	90	level	level	NOUN
egc-209	13	91	at	at	ADP
egc-209	13	92	t	t	PROPN
egc-209	13	93	1	1	NUM
egc-209	13	94	(	(	PUNCT
egc-209	13	95	42.4	42.4	NUM
egc-209	13	96	%	%	NOUN
egc-209	13	97	±	±	NUM
egc-209	13	98	3.4	3.4	NUM
egc-209	13	99	%	%	NOUN
egc-209	13	100	)	)	PUNCT
egc-209	13	101	the	the	DET
egc-209	13	102	level	level	NOUN
egc-209	13	103	t	t	NOUN
egc-209	13	104	3	3	NUM
egc-209	13	105	had	have	VERB
egc-209	13	106	no	no	DET
egc-209	13	107	significant	significant	ADJ
egc-209	13	108	differences	difference	NOUN
egc-209	13	109	and	and	CCONJ
egc-209	13	110	was	be	AUX
egc-209	13	111	lower	low	ADJ
egc-209	13	112	than	than	ADP
egc-209	13	113	the	the	DET
egc-209	13	114	level	level	NOUN
egc-209	13	115	of	of	ADP
egc-209	13	116	t	t	PROPN
egc-209	13	117	2	2	NUM
egc-209	13	118	by	by	ADP
egc-209	13	119	more	more	ADJ
egc-209	13	120	than	than	ADP
egc-209	13	121	30	30	NUM
egc-209	13	122	%	%	NOUN
egc-209	13	123	.	.	PUNCT
egc-209	14	1	conclusion	conclusion	NOUN
egc-209	14	2	as	as	ADP
egc-209	14	3	a	a	DET
egc-209	14	4	result	result	NOUN
egc-209	14	5	of	of	ADP
egc-209	14	6	the	the	DET
egc-209	14	7	ihc	ihc	PROPN
egc-209	14	8	study	study	NOUN
egc-209	14	9	,	,	PUNCT
egc-209	14	10	we	we	PRON
egc-209	14	11	found	find	VERB
egc-209	14	12	that	that	SCONJ
egc-209	14	13	changes	change	NOUN
egc-209	14	14	in	in	ADP
egc-209	14	15	the	the	DET
egc-209	14	16	level	level	NOUN
egc-209	14	17	of	of	ADP
egc-209	14	18	ki-67	ki-67	ADJ
egc-209	14	19	expression	expression	NOUN
egc-209	14	20	in	in	ADP
egc-209	14	21	nephroblastoma	nephroblastoma	NOUN
egc-209	14	22	in	in	ADP
egc-209	14	23	the	the	DET
egc-209	14	24	primary	primary	ADJ
egc-209	14	25	tumor	tumor	NOUN
egc-209	14	26	tissue	tissue	NOUN
egc-209	14	27	corresponded	correspond	VERB
egc-209	14	28	to	to	ADP
egc-209	14	29	the	the	DET
egc-209	14	30	size	size	NOUN
egc-209	14	31	of	of	ADP
egc-209	14	32	the	the	DET
egc-209	14	33	tumor	tumor	NOUN
egc-209	14	34	node	node	NOUN
egc-209	14	35	,	,	PUNCT
egc-209	14	36	as	as	ADV
egc-209	14	37	well	well	ADV
egc-209	14	38	as	as	ADP
egc-209	14	39	the	the	DET
egc-209	14	40	stage	stage	NOUN
egc-209	14	41	of	of	ADP
egc-209	14	42	the	the	DET
egc-209	14	43	tumor	tumor	NOUN
egc-209	14	44	process	process	NOUN
egc-209	14	45	.	.	PUNCT
egc-209	15	1	thus	thus	ADV
egc-209	15	2	,	,	PUNCT
egc-209	15	3	we	we	PRON
egc-209	15	4	confirmed	confirm	VERB
egc-209	15	5	the	the	DET
egc-209	15	6	possibility	possibility	NOUN
egc-209	15	7	of	of	ADP
egc-209	15	8	using	use	VERB
egc-209	15	9	ki-67	ki-67	PUNCT
egc-209	15	10	in	in	ADP
egc-209	15	11	routine	routine	ADJ
egc-209	15	12	ihc	ihc	PROPN
egc-209	15	13	studies	study	NOUN
egc-209	15	14	as	as	ADP
egc-209	15	15	a	a	DET
egc-209	15	16	direct	direct	ADJ
egc-209	15	17	marker	marker	NOUN
egc-209	15	18	characterizing	characterize	VERB
egc-209	15	19	the	the	DET
egc-209	15	20	long	long	ADJ
egc-209	15	21	-	-	PUNCT
egc-209	15	22	term	term	NOUN
egc-209	15	23	prognosis	prognosis	NOUN
egc-209	15	24	of	of	ADP
egc-209	15	25	the	the	DET
egc-209	15	26	tumor	tumor	NOUN
egc-209	15	27	process	process	NOUN
egc-209	15	28	.	.	PUNCT
egc-209	16	1	https://eglobalcongress.com/index.php/egc	https://eglobalcongress.com/index.php/egc	PROPN